BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced Nature Medicine has published its study demonstrating the clinical utility of mNGS testing to identify difficult-to-detect pathogens among adults and children with serious central nervous system infections.

波士顿--（商业新闻短讯）--感染性疾病宏基因组下一代测序（mNGS）的先驱Delve Bio与加利福尼亚大学旧金山分校（UCSF）合作，今天宣布自然医学发表了其研究，证明了mNGS检测的临床实用性，以识别严重中枢神经系统感染的成人和儿童中难以检测到的病原体。

Soon to be widely available through the company’s Delve Detect testing service, the study showed mNGS testing is more sensitive than direct-detection testing..

该研究表明，mNGS测试比直接检测测试更敏感，很快将通过该公司的Delve检测测试服务广泛提供。。

“These findings add to the drumbeat of support for including mNGS as a core tool in the clinical workup for CNS infections,” said Michael Wilson, M.D., Delve Bio co-founder, member of the Board of Directors, and founding director of the UCSF Center for Encephalitis and Meningitis. “mNGS provides an unbiased, complete and definitive tool to quickly rule in or rule out an infection, enabling more timely diagnosis and treatment for patients with meningitis and encephalitis.”.

Delve Bio联合创始人、董事会成员、加州大学旧金山分校脑炎和脑膜炎中心创始主任迈克尔·威尔逊（MichaelWilson）医学博士说：“这些发现进一步支持将MNG作为中枢神经系统感染临床检查的核心工具。”。“mNGS提供了一种公正，完整和明确的工具，可以快速排除或排除感染，从而为脑膜炎和脑炎患者提供更及时的诊断和治疗。”。

The study includes data from more than 4,800 patients who received cerebrospinal fluid (CSF) mNGS testing. Over the 7-year period, mNGS detected 797 organisms from 697 of 4,828 samples (14.4%) representing 437 unique pathogen species; DNA and RNA viruses were identified in nearly three-quarters of cases, as well as broad-based detection of bacteria, fungi, and parasites.

该研究包括来自4800多名接受脑脊液（CSF）mNGS检测的患者的数据。在7年的时间里，mNGS从4828个样本中的697个样本（14.4%）中检测到797种生物，代表437种独特的病原体；在近四分之三的病例中发现了DNA和RNA病毒，并对细菌，真菌和寄生虫进行了广泛的检测。

Analysis of all microbiological test results and clinical adjudication of a subset of more than 1,000 patients who were treated at UCSF showed that 21.8% (48 of 220) of infections were identified by mNGS alone..

对加州大学旧金山分校接受治疗的1000多名患者的所有微生物检测结果和临床判断的分析表明，仅通过MNG即可鉴定出21.8%（220例中的48例）的感染。。

Delve Detect is the company’s flagship cerebrospinal fluid (CSF) testing service, offering sequencing in a state-of-the-art CLIA lab and robust clinical decision support with turnaround times of two days. Ultimately, Delve Detect will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses..

Delve Detect是该公司的旗舰脑脊液（CSF）检测服务，在最先进的CLIA实验室中提供测序和强大的临床决策支持，周转时间为两天。最终，Delve Detect将使更多可能危及生命的神经系统感染患者受益于更快，更全面的诊断。。

“Time is critical in identifying the cause of acute meningitis or encephalitis for appropriate management decisions,” says Kiran Thakur, M.D., Herbert Irving associate professor of neurology at Columbia University Irving Medical Center - New York Presbyterian Hospital. “mNGS testing of CSF may be able to speed the diagnostic process in challenging cases, enabling rapid treatment decisions and ultimately better outcomes.

哥伦比亚大学欧文医学中心-纽约长老会医院神经病学副教授、医学博士基兰·塔库尔（KiranThakur）表示：“时间对于确定急性脑膜炎或脑炎的病因以做出适当的管理决策至关重要。”。“脑脊液的mNGS检测可能能够加速具有挑战性病例的诊断过程，从而实现快速的治疗决策并最终获得更好的结果。

Implementation studies across use settings will help guide its use.”.

跨使用设置的实施研究将有助于指导其使用。”。

Delve Bio launched in June 2023 to commercialize mNGS technology originally developed at UCSF and exclusively licensed to Delve Bio.

Delve Bio于2023年6月推出，旨在将最初在UCSF开发的mNGS技术商业化，并独家授权给Delve Bio。

About Delve Bio, Inc.

关于Delve Bio，Inc。

Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test.

Delve Bio是一家宏基因组下一代测序（mNGS）公司，为实验室和临床医生提供自信诊断常规和罕见传染病所需的见解，从而最大程度地减少有害病原体对人类的影响。通过利用其无偏见的病原体不可知mNGS平台，Delve Bio能够通过一次测试识别多种病原体。

Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors.

该公司由世界基因组学和传染病领域的领导者Charles Chiu博士、Joe DeRisi博士、Michael Wilson博士、Pardis Sabeti博士和Matthew Meyerson博士创立，并得到顶级机构投资者的支持，包括敏锐的Xontogeny Venture Fund II、Section 32和GV，以及领先的个人投资者。

For more information, visit www.delve.bio..

有关更多信息，请访问www.delve.bio。。